Vaccine News: NIAID-Funded Adjuvant Improves Typhoid Vaccine Candidate in Animal Studies

Vaccine candidate may overcome some shortcomings of available typhoid vaccines.

Thursday, August 18, 2022 NIAID-Funded Adjuvant Improves Typhoid Vaccine Candidate in Animal Studies The bacteria that cause typhoid fever are shown under a microscope with a red flagellar stain. Credit: Microbewriter, CC BY-SA 4.0 An investigational typhoid vaccine containing an adjuvant developed with NIAID funding may overcome some of the shortcomings of available typhoid vaccines, according to a paper published in the journal Vaccine. Although several kinds of typhoid vaccines are available, one that is inexpensive and easy to manufacture, and that provides robust and durable protection for people of all ages—especially very young children—remains elusive. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107